Abbott [gZ2AttP4V2a]
Tag: #Yankees Vs Orioles, #wealden council elections 2026, #pistons - cavaliers, #emily deschanel
Welcome back to Griffonomics, where we conduct financial investigations to define the risk before we look at the reward. Today, were unmasking the "Diagnostic Alpha" of Abbott Laboratoriesanalyzing why Robert Ford is "burning the ships" of COVID-era testing to build a precision oncology powerhouse and whether the $21 billion Exact Sciences acquisition is the key to unlocking a $60 billion cancer screening market.
The Risk: We analyze the "Litigation Overhang"examining the 1,700+ NEC infant formula lawsuits and whether recent multi-million dollar verdicts in Missouri and Chicago represent a structural vodafone share price floor or a terminal ceiling for the balance sheet. We detail the "Dilution Warning", investigating the $0.20 EPS hit from acquisition financing that sent the stock to a 52-week low. We examine the Nutrition Sputter, analyzing the 7.7% comparable decline and whether pricing adjustments can actually spark a volume recovery.
The Reward: We define the "Device Engine" Moat, highlighting the 12.5% growth in Electrophysiology driven by the Pulsed Field Ablation (PFA) revolution. We highlight the "Recurring Revenue" Alpha, detailing how 25% of Cologuard tests are 3-year patient rescreens, creating a high-margin diagnostic flywheel. We detail the "Dividend King" Factor, showcasing 54 consecutive years of increases and a valuation that analysts call the "cheapest in a decade".
Chapter Titles
- Intro: From COVID Kits mike vrabel news to Cancer Screening
- Q1 2026 Deep Dive: sequential momentum yankees - orioles vs. the Exact Sciences dilution
- The Oncology Pivot: Why Abbott paid $21B for Cologuard
- Medical Devices: The PFA revolution and 12.5% growth
- FreeStyle Libre: Tapping into the $35B Diabetes TAM
- The Nutrition Crisis: Pricing, Volume, and the Missouri Verdicts
- NEC Litigation Forensics: Unpacking the $495M Missouri verdict
- Exact Sciences Integration: Scaling rescreens and Oncotype DX
- Financial Realities: The $7 Billion Buyback and Dividend King status
- Valuation Debate: 17.7x Earnings vs. 10-Year Historical Averages
- FINAL VERDICT: A High-Alpha Healthcare Giant or a Legal Value Trap?
#ABT #AbbottLaboratories #Oncology #CancerScreening #StockMarket2026 #FinancialAnalysis #Investing #ExactSciences #ValueInvesting #DividendKing #WallStreet #Griffonomics #PortfolioProtection #MedicalDevices #EarningsReview #StrategicPivot #Moat
SUBSCRIBE to Griffonomics: youtube.com/@Griffonomics
Financial Investigations: The Truth Behind the Ticker.
Risk Defined. Portfolio Protected.
LEGAL DISCLAIMER
The content provided on the Griffonomics channel is for informational and educational purposes only and reflects the creator's personal opinions and research for their own portfolio. It is NOT financial advice. Always conduct your own thorough research before making any investment decisions.